Novus Therapeutics Inc fka NVUS

[ListenToMe]

Merger NEW out!

[l2 hunter]

TKAI is seeking approval of a reverse stock split at its upcoming Special Meeting of Stockholders to be held on May 9, 2017 in connection with the Otic Transaction. The Company expects that the reverse stock split, if approved, would help it regain compliance with the listing standards.

[Yo-Yo]

Time to add?

[THEBELGIAN77]

No volume at all since a week, how would you expect a move,when MM's manipulate this?
Aimo,but i'm tired

[THEBELGIAN77]

Share structure: 22.64M issued but 49,9% locked by insiders
What's wrong here? lack of communication from the direction.
But we're also under the asset value, look at the last financials
GL, this will do a up move

[THEBELGIAN77]

hi there, I'm in with 7000 shares @ 0.668$
Glad to see this merge coming in the next weeks.
GLTA

[QUANTUM314]

Loading opportunity

[novicetrader]

TKAI...trying to read and figure out what happened in the 2 weeks between the Prelim & Definitive Proxy filings,for the new company Name/Ticker to be altered from OticPharma/AOME to Novus Therapeutics/NVUS.Maybe it's not an important thing,but was it just snuck out like that?
Can anyone who's been following this reverse merger for a while please chime in please?Thanks.


PRER14A filed on 3/24/17
After completion of the Otic Transaction, Tokai will be renamed “OticPharma, Inc.” and expects to trade on The NASDAQ Global Market under the symbol “AOME.”

DEFM14A filed on 4/7/17
After completion of the Otic Transaction, Tokai will be renamed “Novus Therapeutics, Inc.” and expects to trade on The NASDAQ Global Market under the symbol “NVUS.”

[corncakes0]

To get convos going where do we think merger is going to happen? Tired of this what? Consolidation? Ugh

[Rock_nj]

TKAI's draft proxy filing is under 30 day review with SEC, so this may be dead for 3 weeks.

[LightandShadow]

Nice action here today

[TheMagnetar]

I had a great profit off the last run. Bought back in on this dip ahead of merger deal! Looks like we should see news sometime this week! ~The Wiz

[BullishGuru]

Where do you think we go? $2?

[l2 hunter]

TKAI NEWS Proxy Statement - Merger or Acquistion (preliminary) (prem14a)

[Rock_nj]

Filing expected today or tomorrow per PR firm. 400 pages. Merger details.

[Rock_nj]

Sounds like it will be showtime very soon for $TKAI. Someone on Stocktwits emailed the PR firm and heard back that a proxy filing is imminent with all the company and merger details. We shall see.

[Lone Wolf]

Too manipulated. Watching though. TKAI likes to bounce around current pps. Would have hoped the capitalization information was released with the news of the RM...so needing a bit more clarity first.

[Rock_nj]

Are you still in $TKAI Lone Wolf? Next week might finally be showtime with the conference call announcement, then the call providing merger details.

[Rock_nj]

Conference call announcement coming soon. By end of week I suppose. TKAI is primed to move higher.

[Rock_nj]

I am certainly looking forward to hearing what the new Otic management has to say. From everything I've read, the new post-merger company has a lot of potential and has management taking over that have a track record of success.

[corncakes0]

Hoping the CC is next week as they said "early January." This gem is ready to explode!

[Rock_nj]

Otic Pharma, Ltd. just filed a new activist 13D, reporting 39.3% ownership in $TKAI.

[Rock_nj]

Otic Pharma merging into Tokai Nasdaq shell

Otic's shareholders will invest $7 million in the merged company.

Otic Pharma, which develops ear, nose, and throat (ENT) treatments, has announced its merger with Nasdaq shell Tokai Pharmaceuticals. Otic main drug is used for treatment of middle ear infections in children.

The parties will exchange shares. Following the deal, Otic's shareholders will own 60% of the merged company, and Tokai's shareholders 40%. The listed company, which will change its name to Otic Pharma and develop Otic's products, will be managed by Otic CEO Gregory Flesher.

Tokay is listed on Nasdaq at a $24 million market cap, after its share price fell 10%, following the announcement. Tokay had $34 million in cash at the end of the third quarter of 2016, and Otic's shareholders agreed to invest $7 million more in the company. Israeli funds OrbiMed Israel, Pontifax, and Peregrine Ventures control Otic, which also obtained a direct investment from former Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) chairman and Opko Health Inc. (NYSE: OPK; TASE: OPK) CEO Phillip Frost. Together with Peregrine, Frost invested in the Intensive incubator in which Otic developed.

Otic's leading product is a nasally administered drug for treating the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) more completely than the existing treatments. Initial clinical results from the product are due in mid-2017. The company said that the listed company's cash, combined with the additional investment, should be enough for the the merged company to commence Phase II clinical trials for treatment of ears in children.

http://www.globes.co.il/en/article-otic-pharma-merging-into-nasdaq-listed-co-tokai-1001168564

[Rock_nj]

TKAI is heating up. Going to be a runaway train higher once news hits the wires regarding the conference call detailing the merger. Then rally higher from there most likely.

[Rock_nj]

TKAI short covering rally has begun ahead of conference call announcement and presentation to industry players in San Francisco next week.

[Rock_nj]

Tax loss selling of TKAI is almost over. Next week is short covering followed by news of the press conference, then a presentation by new Optic management at an industry conference in San Francisco. This stock could get legs really quickly in January.

[Rock_nj]

Add to these, the end of tax loss selling and likely short-covering in early 2017 ahead of the conference call and additional merger news and TKAI is likely to have a nice recovering from the $1 level.

[Rock_nj]

Two big developments for TKAI early in January:

1) J.P. Morgan 35th Annual Healthcare Conference
January 9th through 13th 2017

Leadership from OticPharma's will be attending J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco. If you would like to meet with them at this conference, please contact us.

2) The Conference Call during "early January" per the PR last week, that will discuss the reverse merger in more detail.

[Rock_nj]

TKAI is going to spike once the conference call happens early in January.

[Rock_nj]

Boston-based Tokai throws in the towel, sells public shell to Israeli biotech

A Boston-based drug developer incorporated 12 years ago which stopped development of it’s lead drug for prostate cancer this past summer has transferred its publicly-traded shell to an Israeli firm.

Tokai Pharmaceuticals (Nasdaq: TKAI) and Otic Pharma Ltd., which is developing drugs for disorders of the ear, nose, and throat, announced a share purchase agreement Thursday under which the shareholders of Otic will become the majority owners of Tokai. The new company will operate under the name OticPharma and will be led by Gregory J. Flesher, current CEO of Otic Pharma, while Tokai’s president and CEO Jodie Morrison will become a member of the new board of directors.

Shareholders of Otic Pharma will receive a total of 32 million shares of newly-issued Tokai stock, while outstanding Otic Pharma options and convertible securities will be assumed by Tokai. Tokai stockholders will end up owning about 40 percent of the new company, and Otic’s will owning the other 60 percent. The transaction has been unanimously approved by the boards of directors of both companies and shareholders of Otic Pharma.

Tokai’s largest stockholder, New York-based Apple Tree Partners, held approximately 35 percent of Tokai’s common stock, before the transaction, which is expected to close during the first quarter of 2017.

The move means one fewer of the more than 80 Nasdaq-traded biotech firms based in Massachusetts, coming five months after Tokai halted a late-stage trial of its potential prostate cancer drug, called galeterone, because it determined it probably would have failed. The company’s shares fell to a quarter of what they were previously within a few hours of trading, giving the company a market value that was less than than the amount of cash the company had on hand at the time. It laid off 10 employees, more than half it’s total staff, in the following days.

“Over the last several months, Tokai has conducted an extensive review of strategic alternatives aimed at maximizing value for our shareholders over the long-term,” said Morrison in a statement yesterday. “We believe the proposed transaction with Otic Pharma, a company that has both a promising pipeline and an experienced leadership team with a track record of creating significant shareholder value in public pharmaceutical companies, advances this goal.”

On Thursday, Tokai’s shares closed up 20 percent after the announcement.

A Boston-based drug developer incorporated 12 years ago which stopped development of it’s lead drug for prostate cancer this past summer has transferred its publicly-traded shell to an Israeli firm.

Tokai Pharmaceuticals (Nasdaq: TKAI) and Otic Pharma Ltd., which is developing drugs for disorders of the ear, nose, and throat, announced a share purchase agreement Thursday under which the shareholders of Otic will become the majority owners of Tokai. The new company will operate under the name OticPharma and will be led by Gregory J. Flesher, current CEO of Otic Pharma, while Tokai’s president and CEO Jodie Morrison will become a member of the new board of directors.

Jodie Morrison CEO, Tokai Pharmaceuticals Inc.
Enlarge
Jodie Morrison CEO, Tokai Pharmaceuticals Inc.

M. SHAWN READ

Shareholders of Otic Pharma will receive a total of 32 million shares of newly-issued Tokai stock, while outstanding Otic Pharma options and convertible securities will be assumed by Tokai. Tokai stockholders will end up owning about 40 percent of the new company, and Otic’s will owning the other 60 percent. The transaction has been unanimously approved by the boards of directors of both companies and shareholders of Otic Pharma.

Tokai’s largest stockholder, New York-based Apple Tree Partners, held approximately 35 percent of Tokai’s common stock, before the transaction, which is expected to close during the first quarter of 2017.

The move means one fewer of the more than 80 Nasdaq-traded biotech firms based in Massachusetts, coming five months after Tokai halted a late-stage trial of its potential prostate cancer drug, called galeterone, because it determined it probably would have failed. The company’s shares fell to a quarter of what they were previously within a few hours of trading, giving the company a market value that was less than than the amount of cash the company had on hand at the time. It laid off 10 employees, more than half it’s total staff, in the following days.

“Over the last several months, Tokai has conducted an extensive review of strategic alternatives aimed at maximizing value for our shareholders over the long-term,” said Morrison in a statement yesterday. “We believe the proposed transaction with Otic Pharma, a company that has both a promising pipeline and an experienced leadership team with a track record of creating significant shareholder value in public pharmaceutical companies, advances this goal.”



On Thursday, Tokai’s shares closed up 20 percent after the announcement.

[Rock_nj]

TKAI ambling along until the conference call in early January that will lay out what this merger means. Kind of surprised it's not trading higher than the $1 level that it was at for many months, now that a dead company has new life breathed into it, but the stock market can act in odd ways at times. I have a feeling after the conference call and more info comes out about the pending merger, this stock is going to be a winner.

[Rock_nj]

Right back up again to the $1.20s after an early dip. Early January will be the conference call to lay this all out. I think buyers here will be happy. This went to $2 in October on nothing substantial. This merger news is very substantial!

[Lonewolf1]

Gapping down aftr yesterday afternoon's sustained dumpfest.

Back to $1 again by EOD? :D

[rogueT]

The problem is, that this Otic Pharma has basically nothing to show for. Their drug candidates are only investigational.
That also explains the 60/40 ownership split. But two companies that are worth nothing combined still dont amount to much.
And worse than this, Ortic will use TKAI as an ATM and continually dump new shares on the market, thats why they do this transaction in the first place.
Reverse merger stories are often great for trading, but I doubt that this one will be such an opportunity

[Rock_nj]

Conference Call Information

Tokai and Otic Pharma will host a conference call in early January to discuss the proposed transaction. Call in information will be provided in a future press release.
-----

Average down. More spikes higher are coming. Can't wait for this conference call in early January.

[Rock_nj]

I don't see how this has anywhere to go but up. People who sold today booked good profits from the $1 level. Stronger hands will become holders of this stock over time, as the merger draws near and up goes the price. Both boards have approved the merger and it is set to close Q1 2017. Not a long wait or uncertain outcome. Actually, one of the best RM share exchanges I've seen for existing shareholders.

[Lone Wolf]

Surprised here too. When 3 times the float trades, it's pretty clear why this didn't go much higher.

That said, had the company provided some guidance as to their approximate valuation at the end of the merger, it would not have been so easy for the shorts to pile on. The more important item is the company's survival as a new entity. TKAI will do okay.

[christalball]

Just up 20% from the bottom.

[christalball]

Surprised by EOD.
I think 1.20 is a great value price.
I guess mostly day traders here today.

[ClayTrader]

* * $TKAI Video Chart 12-22-16 * *

Link to Video - click here to watch the technical chart video

[Rock_nj]

Flippers out. Grind higher. This appears to be a done deal closing in early 2017. More upside ahead!

[Wild Wild West]

Nice inverted hammer here. Should see a huge price move north over the next few trading days. Could easily go back to the $5 range. Going long here now!Giddy up TKAI

[l2 hunter]

TKAI going into. Eod $1.40 range i think. Gapper tomorrow

[christalball]

Looking a little better.

[DieselJoe]

This is why I follow you.

[christalball]

I agree with you.

[christalball]

Screw it.
I bought more.

[l2 hunter]

TKAI now with real future. The Merger is huge for TKAI. Multi day move start. New revaluation start imo.

[christalball]

Just want more cheapies I guess.

[christalball]

Can't believe all these people are dumping
at these low prices for meager gains compared to potential.